10 January 2022 |

Medtronic to Acquire Affera

DUBLIN, Jan. 10, 2022 — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it has entered into a definitive agreement to acquire Affera, Inc., a Boston area-based, privately held medical technology company. Affera designs and manufactures cardiac mapping and navigation systems and catheter-based cardiac ablation technologies, including a differentiated, focal pulsed field ablation solution, for the treatment of

Tags:
01 September 2021 |

Chardan Announces Stockholder Approval Of Business Combination With Renovacor

NEW YORK, Sept. 1, 2021 — Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) (“CHAQ”), a special purpose acquisition company sponsored by Chardan Capital Markets (“Chardan”), today announced the results for the proposals considered and voted upon by its stockholders at its special meeting held on September 1, 2021 (the “Special Meeting”), regarding the proposed business combination with Renovacor, Inc. (“Renovacor”),

Tags:
12 July 2021 |

EryDel Announces Top-line Results from Phase 3 ATTeST Trial

BRESSO, JULY 12th 2021 – EryDel SpA, a global late-stage biotech company aimed at developing and commercializing therapies for the treatment of rare diseases delivered by its proprietary red blood cell technology announced today topline results from its Phase 3 ATTeST clinical trial in patients with Ataxia Telangiectasia (AT), a devastating neurological disease for which there is no approved therapy.

Tags:
06 October 2021 |

Anaconda Biomed to close venture debt operation of up to €10 million with the EIB

BARCELONA, OCTOBER 6th 2021 – Anaconda Biomed to close venture debt operation of up to €10 million with the EIB to treat acute ischemic stroke (AIS).  EIB to provide venture debt funding of up to €10 million to support the development of Anaconda’s next generation of catheters to treat acute ischemic strokes (AIS). This venture debt operation is supported by the European Guarantee

Tags:
20 April 2021 |

Pi-Cardia Closes a $27 Million Financing

REHOVOT, APRIL 20th 2020 – Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for treating heart valve calcification, announced today it has closed a $27 million round of financing, led by Sofinnova Partners, a leading European life sciences venture capital firm, and joined by Professor Jacques Séguin, Chairman of the company, with further participation from existing

Tags:
12 April 2021 |

GreenBone closes a € 10 million Series B round

3B Future Health Fund, (formerly Helsinn Investment Fund), Innogest SGR, Meta Group, CDP Venture Capital Sgr, Italian Angels for Growth and other private investors - subscribed a new capital increase to allow the company to reach new and important milestones in the field of bone regeneration

Tags:
10 February 2021 |

MedLumics closes upsized 18M€ financing round

MADRID, FEBRUARY 10th 2021 – MedLumics, a privately held medical device company developing AblaView, the first optically-guided real-time ablation catheter system for the treatment of Atrial Fibrillation (AF), announced today that it has closed an upsized EUR 18 million (USD 21.7 million) financing round and has appointed Rich Ferrari as Chairman of the Board of Directors. MedLumics’ optical catheter displays

Tags:
07 January 2021 |

Pi-Cardia Successfully Treats First Patients with ShortCut Device

REHOVOT, JANUARY 7th 2021 – Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based solutions for treating heart valves, announced today successful first-in-human procedures with its ShortCut™ device. ShortCut™ is the world’s first dedicated device designed to split the leaflets of a pre-existing valve to enable safe Transcatheter Aortic Valve Replacement (TAVR) in patients at risk for coronary

Tags:
01 November 2020 |

Angiodroid won the X edition of Gaetano Marzotto Company Prize

Angiodroid wins the Company Prize as the best innovative company with the ability to generate significant positive effects in the social, territorial, cultural or environmental areas. Angiodroid doubles, also winning the special prize Unicredit Starlab, entering the Unicredit project to support young entrepreneurs, innovation and new technologies. Here is an excerpt from the award ceremony, from the words of Diana Saraceni,

Tags:
>